Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial
Highlights • Sepranolone (UC1010) is a GABAA modulating steroid antagonist to the progesterone metabolite allopregnanolone, which is probably causing the negative mood in women with premenstrual dysphoric disorder (PMDD). • In this randomized placebo-controlled parallel group trial UC1010 treatment...
Gespeichert in:
| Veröffentlicht in: | Psychoneuroendocrinology 2017-06, Vol.80, p.46-55 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | |
| container_start_page | 46 |
| container_title | Psychoneuroendocrinology |
| container_volume | 80 |
| creator | Bixo, Marie Ekberg, Karin Poromaa, Inger Sundström Hirschberg, Angelica Lindén Jonasson, Aino Fianu Andréen, Lotta Timby, Erika Wulff, Marianne Ehrenborg, Agneta Bäckström, Torbjörn |
| description | Highlights • Sepranolone (UC1010) is a GABAA modulating steroid antagonist to the progesterone metabolite allopregnanolone, which is probably causing the negative mood in women with premenstrual dysphoric disorder (PMDD). • In this randomized placebo-controlled parallel group trial UC1010 treatment during the premenstrual phase reduced negative mood symptoms significantly better than placebo in women with a well-defined PMDD. • The effect size was comparable to that of SSRIs and drospirenone containing oral contraceptives. • UC1010 was well tolerated and deemed safe. |
| doi_str_mv | 10.1016/j.psyneuen.2017.02.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_elsev</sourceid><recordid>TN_cdi_proquest_miscellaneous_1879661645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306453016309180</els_id><sourcerecordid>1879661645</sourcerecordid><originalsourceid>FETCH-LOGICAL-e215t-9de27bd787ef6dccf4b39feee0c352f76f7ffb4e0485423554ecf8cd468d40873</originalsourceid><addsrcrecordid>eNpdkUGOEzEQRS0EEiFwBeTlsEhTbne7OxtEiGBAGonFzKwtxy5PHBy7sd2DwopDIHE_ToKjgQ2r-ov6X1X_EfKSQcOAideHZsqngDOGpgU2NNA2wNkjsmDjwFecC3hMFsBBrLqew1PyLOcDAIhRtAvy6yahKkcMhUZLp4RV5pJm5ak55Wkfk9PUuByTwUS_ubKnZY_0cvNus6EJNU4lJnqMZvaquHBHc8EUnaEqFHUXg8uFXuOUVIg-BqQXt9t6NLz6_eNn9atg4tF9R0N1DCVF76ssySn_nDyxymd88Xcuye2H9zfbj6urz5eftpurFbasL6u1wXbYmWEc0Aqjte12fG0RETTvWzsIO1i76xC6se9a3vcdajtq04nRdFD7WZKLh9wpxa8z5iKPLmv0XgWMc5a1w7UQTNTqluTtwyrWe-4dJpm1w6DRuFpEkSY6yUCemciD_MdEnplIaGVlUiPe_BehvQtOK_8FT5gPcU6hfiuZzNUgr8_UztCY4LBmI_A_hKCdDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1879661645</pqid></control><display><type>article</type><title>Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Bixo, Marie ; Ekberg, Karin ; Poromaa, Inger Sundström ; Hirschberg, Angelica Lindén ; Jonasson, Aino Fianu ; Andréen, Lotta ; Timby, Erika ; Wulff, Marianne ; Ehrenborg, Agneta ; Bäckström, Torbjörn</creator><creatorcontrib>Bixo, Marie ; Ekberg, Karin ; Poromaa, Inger Sundström ; Hirschberg, Angelica Lindén ; Jonasson, Aino Fianu ; Andréen, Lotta ; Timby, Erika ; Wulff, Marianne ; Ehrenborg, Agneta ; Bäckström, Torbjörn</creatorcontrib><description>Highlights • Sepranolone (UC1010) is a GABAA modulating steroid antagonist to the progesterone metabolite allopregnanolone, which is probably causing the negative mood in women with premenstrual dysphoric disorder (PMDD). • In this randomized placebo-controlled parallel group trial UC1010 treatment during the premenstrual phase reduced negative mood symptoms significantly better than placebo in women with a well-defined PMDD. • The effect size was comparable to that of SSRIs and drospirenone containing oral contraceptives. • UC1010 was well tolerated and deemed safe.</description><identifier>ISSN: 0306-4530</identifier><identifier>EISSN: 1873-3360</identifier><identifier>DOI: 10.1016/j.psyneuen.2017.02.031</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Allopregnanolone ; Endocrinology & Metabolism ; GABA ; Isoallopregnanolone ; Premenstrual dysphoric disorder ; Psychiatry ; Randomized controlled trial</subject><ispartof>Psychoneuroendocrinology, 2017-06, Vol.80, p.46-55</ispartof><rights>2017 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306453016309180$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids></links><search><creatorcontrib>Bixo, Marie</creatorcontrib><creatorcontrib>Ekberg, Karin</creatorcontrib><creatorcontrib>Poromaa, Inger Sundström</creatorcontrib><creatorcontrib>Hirschberg, Angelica Lindén</creatorcontrib><creatorcontrib>Jonasson, Aino Fianu</creatorcontrib><creatorcontrib>Andréen, Lotta</creatorcontrib><creatorcontrib>Timby, Erika</creatorcontrib><creatorcontrib>Wulff, Marianne</creatorcontrib><creatorcontrib>Ehrenborg, Agneta</creatorcontrib><creatorcontrib>Bäckström, Torbjörn</creatorcontrib><title>Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial</title><title>Psychoneuroendocrinology</title><description>Highlights • Sepranolone (UC1010) is a GABAA modulating steroid antagonist to the progesterone metabolite allopregnanolone, which is probably causing the negative mood in women with premenstrual dysphoric disorder (PMDD). • In this randomized placebo-controlled parallel group trial UC1010 treatment during the premenstrual phase reduced negative mood symptoms significantly better than placebo in women with a well-defined PMDD. • The effect size was comparable to that of SSRIs and drospirenone containing oral contraceptives. • UC1010 was well tolerated and deemed safe.</description><subject>Allopregnanolone</subject><subject>Endocrinology & Metabolism</subject><subject>GABA</subject><subject>Isoallopregnanolone</subject><subject>Premenstrual dysphoric disorder</subject><subject>Psychiatry</subject><subject>Randomized controlled trial</subject><issn>0306-4530</issn><issn>1873-3360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdkUGOEzEQRS0EEiFwBeTlsEhTbne7OxtEiGBAGonFzKwtxy5PHBy7sd2DwopDIHE_ToKjgQ2r-ov6X1X_EfKSQcOAideHZsqngDOGpgU2NNA2wNkjsmDjwFecC3hMFsBBrLqew1PyLOcDAIhRtAvy6yahKkcMhUZLp4RV5pJm5ak55Wkfk9PUuByTwUS_ubKnZY_0cvNus6EJNU4lJnqMZvaquHBHc8EUnaEqFHUXg8uFXuOUVIg-BqQXt9t6NLz6_eNn9atg4tF9R0N1DCVF76ssySn_nDyxymd88Xcuye2H9zfbj6urz5eftpurFbasL6u1wXbYmWEc0Aqjte12fG0RETTvWzsIO1i76xC6se9a3vcdajtq04nRdFD7WZKLh9wpxa8z5iKPLmv0XgWMc5a1w7UQTNTqluTtwyrWe-4dJpm1w6DRuFpEkSY6yUCemciD_MdEnplIaGVlUiPe_BehvQtOK_8FT5gPcU6hfiuZzNUgr8_UztCY4LBmI_A_hKCdDg</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Bixo, Marie</creator><creator>Ekberg, Karin</creator><creator>Poromaa, Inger Sundström</creator><creator>Hirschberg, Angelica Lindén</creator><creator>Jonasson, Aino Fianu</creator><creator>Andréen, Lotta</creator><creator>Timby, Erika</creator><creator>Wulff, Marianne</creator><creator>Ehrenborg, Agneta</creator><creator>Bäckström, Torbjörn</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>7X8</scope></search><sort><creationdate>20170601</creationdate><title>Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial</title><author>Bixo, Marie ; Ekberg, Karin ; Poromaa, Inger Sundström ; Hirschberg, Angelica Lindén ; Jonasson, Aino Fianu ; Andréen, Lotta ; Timby, Erika ; Wulff, Marianne ; Ehrenborg, Agneta ; Bäckström, Torbjörn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e215t-9de27bd787ef6dccf4b39feee0c352f76f7ffb4e0485423554ecf8cd468d40873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Allopregnanolone</topic><topic>Endocrinology & Metabolism</topic><topic>GABA</topic><topic>Isoallopregnanolone</topic><topic>Premenstrual dysphoric disorder</topic><topic>Psychiatry</topic><topic>Randomized controlled trial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bixo, Marie</creatorcontrib><creatorcontrib>Ekberg, Karin</creatorcontrib><creatorcontrib>Poromaa, Inger Sundström</creatorcontrib><creatorcontrib>Hirschberg, Angelica Lindén</creatorcontrib><creatorcontrib>Jonasson, Aino Fianu</creatorcontrib><creatorcontrib>Andréen, Lotta</creatorcontrib><creatorcontrib>Timby, Erika</creatorcontrib><creatorcontrib>Wulff, Marianne</creatorcontrib><creatorcontrib>Ehrenborg, Agneta</creatorcontrib><creatorcontrib>Bäckström, Torbjörn</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>MEDLINE - Academic</collection><jtitle>Psychoneuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bixo, Marie</au><au>Ekberg, Karin</au><au>Poromaa, Inger Sundström</au><au>Hirschberg, Angelica Lindén</au><au>Jonasson, Aino Fianu</au><au>Andréen, Lotta</au><au>Timby, Erika</au><au>Wulff, Marianne</au><au>Ehrenborg, Agneta</au><au>Bäckström, Torbjörn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial</atitle><jtitle>Psychoneuroendocrinology</jtitle><date>2017-06-01</date><risdate>2017</risdate><volume>80</volume><spage>46</spage><epage>55</epage><pages>46-55</pages><issn>0306-4530</issn><eissn>1873-3360</eissn><abstract>Highlights • Sepranolone (UC1010) is a GABAA modulating steroid antagonist to the progesterone metabolite allopregnanolone, which is probably causing the negative mood in women with premenstrual dysphoric disorder (PMDD). • In this randomized placebo-controlled parallel group trial UC1010 treatment during the premenstrual phase reduced negative mood symptoms significantly better than placebo in women with a well-defined PMDD. • The effect size was comparable to that of SSRIs and drospirenone containing oral contraceptives. • UC1010 was well tolerated and deemed safe.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.psyneuen.2017.02.031</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-4530 |
| ispartof | Psychoneuroendocrinology, 2017-06, Vol.80, p.46-55 |
| issn | 0306-4530 1873-3360 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1879661645 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Allopregnanolone Endocrinology & Metabolism GABA Isoallopregnanolone Premenstrual dysphoric disorder Psychiatry Randomized controlled trial |
| title | Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T19%3A02%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20premenstrual%20dysphoric%20disorder%20with%20the%20GABAA%20receptor%20modulating%20steroid%20antagonist%20Sepranolone%20(UC1010)%E2%80%94A%20randomized%20controlled%20trial&rft.jtitle=Psychoneuroendocrinology&rft.au=Bixo,%20Marie&rft.date=2017-06-01&rft.volume=80&rft.spage=46&rft.epage=55&rft.pages=46-55&rft.issn=0306-4530&rft.eissn=1873-3360&rft_id=info:doi/10.1016/j.psyneuen.2017.02.031&rft_dat=%3Cproquest_elsev%3E1879661645%3C/proquest_elsev%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1879661645&rft_id=info:pmid/&rft_els_id=S0306453016309180&rfr_iscdi=true |